NASDAQ:NDRM NeuroDerm Ltd. - Ordinary Share (NDRM) Stock Price, News & Analysis → Don’t Miss Out on the AI Gold Rush That’s Just Getting Started (From Banyan Hill Publishing) (Ad) Free NDRM Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Share Share Today's Range$38.85▼$38.8550-Day Range N/A52-Week Range$15.20▼$38.95VolumeN/AAverage Volume418,712 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get NeuroDerm Ltd. - Ordinary Share alerts: Email Address Ad Banyan Hill PublishingDon’t Miss Out on the AI Gold Rush That’s Just Getting Started“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.See how you can invest alongside him About NeuroDerm Ltd. - Ordinary Share Stock (NASDAQ:NDRM)NeuroDerm Ltd. is an Israel-based clinical-stage pharmaceutical company. The Company is engaged in developing treatments for central nervous system (CNS) disorders, primarily Parkinson's disease, as well as other CNS diseases. The Company's Parkinson's disease product candidates are drug-device combination products, with devices and varying levodopa (LD)/carbidopa (CD) or apomorphine concentrations and dosages. Its liquid LD/CD and apomorphine formulations include ND0612H, ND0612L and ND0701. It is developing ND0612H for the treatment of patients suffering from severe Parkinson's disease. It is developing ND0612L for the treatment of patients at the moderate stage of Parkinson's disease that can no longer control motor complications with oral levodopa. It has also designed ND0701, which is an apomorphine-based product. ND0701 is for patients suffering from Parkinson's disease, may be used mostly by patients suffering from high motor fluctuations and not responding well to LD/CD.Read More Ad Banyan Hill PublishingDon’t Miss Out on the AI Gold Rush That’s Just Getting Started“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.See how you can invest alongside him NDRM Stock News HeadlinesApril 18, 2024 | nasdaq.comInternational Tower Hill Mines, Ltd. Ordinary Shares (Canada) (THM)April 17, 2024 | money.usnews.comHamilton Insurance Group Ltd. - Ordinary Shares - Class BApril 24, 2024 | Banyan Hill Publishing (Ad)Don’t Miss Out on the AI Gold Rush That’s Just Getting Started“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.April 6, 2024 | morningstar.comAshnisha Industries Ltd Ordinary SharesMarch 29, 2024 | msn.comRemgro Limited Announces On-market Share Purchases by Senior ExecutivesMarch 2, 2024 | morningstar.comGenusPlus Group Ltd Ordinary SharesFebruary 27, 2024 | morningstar.comAutoStore Holdings Ltd Ordinary Shares AUTOFebruary 27, 2024 | morningstar.comSibanye Stillwater Ltd Ordinary SharesApril 24, 2024 | Banyan Hill Publishing (Ad)Don’t Miss Out on the AI Gold Rush That’s Just Getting Started“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.February 27, 2024 | morningstar.comBorosil Ltd Ordinary Shares BOROLTDFebruary 9, 2024 | morningstar.comDuratec Ltd Ordinary Shares DURFebruary 9, 2024 | morningstar.comBorosil Ltd Ordinary SharesFebruary 1, 2024 | morningstar.comArgenica Therapeutics Ltd Ordinary SharesJanuary 31, 2024 | morningstar.comKyoritsu Co Ltd Ordinary Shares 7795January 23, 2024 | morningstar.comCiti Pharma Ltd Ordinary SharesDecember 12, 2023 | morningstar.comKukjeon Pharmaceutical Co Ltd Ordinary Shares 307750December 9, 2023 | morningstar.comBiolidics Ltd Ordinary SharesNovember 16, 2023 | morningstar.comBeta Drugs Ltd Ordinary Shares BETANovember 16, 2023 | morningstar.comNanoTIM Co Ltd Ordinary SharesNovember 8, 2023 | morningstar.comHighcon Systems Ltd Ordinary SharesNovember 3, 2023 | morningstar.comKainantu Resources Ltd Ordinary SharesNovember 1, 2023 | morningstar.comMoneyHero Ltd Ordinary Shares - Class AOctober 13, 2023 | morningstar.comVS Media Holdings Ltd Ordinary Shares Class ASeptember 14, 2023 | morningstar.comGolden Heaven Group Holdings Ltd Ordinary Shares - Class AAugust 31, 2023 | money.usnews.comVirax Biolabs Group Ltd - Ordinary Shares - Class AAugust 22, 2023 | morningstar.comHimal Dolakha Hydropower Co Ltd Ordinary SharesAugust 9, 2023 | money.usnews.comGolden Sun Education Group Ltd - Ordinary Shares - Class ASee More Headlines Receive NDRM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NeuroDerm Ltd. - Ordinary Share and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/11/2017Today4/24/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorN/A Industry N/A Sub-IndustryN/A Current SymbolNASDAQ:NDRM CUSIPN/A CIK1598696 Webneuroderm.com Phone+972-8-9462729FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A The Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesRobert TaubChairman of the BoardOded S. LiebermannChief Executive Officer, DirectorRoy Golan CPAChief Financial OfficerBio & Compensation - Tami YardeniChief Operating OfficerBio & Compensation - Sharon Cohen-Vered Ph.D.Vice President - CMC & QASheila OrenVice President - Clinical and Regulatory AffairsEran ShorVice President - DevicesBio & Compensation - Oron Yacoby-ZeeviVice President - Research & DevelopmentRevital Mandil-Levin Ph.D.Head - Business DevelopmentShmuel CabillyDirectorMore Executives NDRM Stock Analysis - Frequently Asked Questions How were NeuroDerm Ltd. - Ordinary Share's earnings last quarter? NeuroDerm Ltd. - Ordinary Share (NASDAQ:NDRM) released its quarterly earnings data on Thursday, May, 11th. The biotechnology company reported ($0.25) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.38) by $0.13. What other stocks do shareholders of NeuroDerm Ltd. - Ordinary Share own? Based on aggregate information from My MarketBeat watchlists, some companies that other NeuroDerm Ltd. - Ordinary Share investors own include Puma Biotechnology (PBYI), (MDVN) (MDVN), BioMarin Pharmaceutical (BMRN), Incyte (INCY), First Solar (FSLR), (KITE) (KITE), Dynavax Technologies (DVAX), United Airlines (UAL), Array Technologies (ARRY) and Freeport-McMoRan (FCX). When did NeuroDerm Ltd. - Ordinary Share IPO? NeuroDerm Ltd. - Ordinary Share (NDRM) raised $45 million in an initial public offering (IPO) on Friday, November 14th 2014. The company issued 4,500,000 shares at a price of $10.00 per share. Jefferies and Cowen and Company acted as the underwriters for the IPO and Oppenheimer and Roth Capital Partners were co-managers. This page (NASDAQ:NDRM) was last updated on 4/24/2024 by MarketBeat.com Staff From Our Partnerstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencySHOCKING Crypto Leak…Crypto 101 MediaYour Money is Not SafeAmerican AlternativeDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingMan Who Predicted 2008: “This Will be Worse.”AltimetryEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest MetalsBiden out June 13; Kamala won’t replace him?Paradigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NeuroDerm Ltd. - Ordinary Share Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
